Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Increased mTOR activation in idiopathic multicentric Castleman disease.

Arenas DJ, Floess K, Kobrin D, Pai RL, Srkalovic MB, Tamakloe MA, Rasheed R, Ziglar J, Khor J, Parente SAT, Pierson SK, Martinez D, Wertheim GB, Kambayashi T, Baur J, Teachey DT, Fajgenbaum DC.

Blood. 2020 Mar 23. pii: blood.2019002792. doi: 10.1182/blood.2019002792. [Epub ahead of print]

PMID:
32206779
2.

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.

Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS.

J Clin Invest. 2019 Aug 13;130:4451-4463. doi: 10.1172/JCI126091.

3.

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.

Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC.

Br J Haematol. 2019 Jan;184(2):232-241. doi: 10.1111/bjh.15588. Epub 2018 Sep 11.

PMID:
30203839
4.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.

Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.

5.

Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.

Pierson SK, Stonestrom AJ, Shilling D, Ruth J, Nabel CS, Singh A, Ren Y, Stone K, Li H, van Rhee F, Fajgenbaum DC.

Am J Hematol. 2018 Jul;93(7):902-912. doi: 10.1002/ajh.25123. Epub 2018 May 16.

6.

Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial.

Courcoulas AP, Belle SH, Neiberg RH, Pierson SK, Eagleton JK, Kalarchian MA, DeLany JP, Lang W, Jakicic JM.

JAMA Surg. 2015 Oct;150(10):931-40. doi: 10.1001/jamasurg.2015.1534.

7.

Urinary Incontinence Before and After Bariatric Surgery.

Subak LL, King WC, Belle SH, Chen JY, Courcoulas AP, Ebel FE, Flum DR, Khandelwal S, Pender JR, Pierson SK, Pories WJ, Steffen KJ, Strain GW, Wolfe BM, Huang AJ.

JAMA Intern Med. 2015 Aug;175(8):1378-87. doi: 10.1001/jamainternmed.2015.2609.

8.

Cognition in children with sensorineural hearing loss: etiologic considerations.

Pierson SK, Caudle SE, Krull KR, Haymond J, Tonini R, Oghalai JS.

Laryngoscope. 2007 Sep;117(9):1661-5.

9.

Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone.

Helton DR, Osborne DW, Pierson SK, Buonarati MH, Bethem RA.

Drug Metab Dispos. 2000 Aug;28(8):925-9.

PMID:
10901702

Supplemental Content

Loading ...
Support Center